{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:09:25Z","timestamp":1777874965525,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tracli.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:56:19Z","timestamp":1769586979000},"page":"79-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practice variability in the evaluation and management of HLA alloimmunization in platelet refractoriness: a multi-institutional survey in the USA"],"prefix":"10.1016","volume":"33","author":[{"given":"Yigit","family":"Baykara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh-Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muharrem","family":"Yunce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2026.01.009_b0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"Hod","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2026.01.009_b0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/hematology.2020000137","article-title":"Platelet transfusion refractoriness: how do I diagnose and manage?","volume":"2020","author":"Cohn","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.tracli.2026.01.009_b0015","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.01.009_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2003-03-0940","article-title":"Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness","volume":"103","author":"Seftel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.01.009_b0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1537-2995.1992.32792391036.x","article-title":"Selection of platelets for refractory patients by HLA matching and prospective crossmatching","volume":"32","author":"Moroff","year":"1992","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2026.01.009_b0030","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1046\/j.1537-2995.2000.40121446.x","article-title":"Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity","volume":"40","author":"Petz","year":"2000","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2026.01.009_b0035","first-page":"271","article-title":"Survey of current practice for monitoring and management of platelet refractoriness in Italy","volume":"47","author":"Quaglietta","year":"2012","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.tracli.2026.01.009_b0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2026.01.009_b0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2026.01.009_b0050","article-title":"AABB and ICTMG international clinical practice guidelines","volume":"2025","author":"Metcalf","year":"2025","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tracli.2026.01.009_b0055","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/trf.16430","article-title":"Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets","volume":"61","author":"Karafin","year":"2021","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2026.01.009_b0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/trf.13598","article-title":"C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants","volume":"56","author":"Jackman","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2026.01.009_b0065","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.V70.5.1433.1433","article-title":"High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion","volume":"70","author":"Zeigler","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.01.009_b0070","article-title":"Therapeutic plasma exchange in alloimmune platelet refractoriness","volume":"62","author":"Raza","year":"2023","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.tracli.2026.01.009_b0075","article-title":"Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim","volume":"62","author":"Kre\u010dak","year":"2023","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.tracli.2026.01.009_b0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/09537104.2014.895922","article-title":"Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness","volume":"26","author":"Cid","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.tracli.2026.01.009_b0085","doi-asserted-by":"crossref","unstructured":"Gao Z, Pan H, Zhang L, Li W, Li R, Zhao J, et al. Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia. Blood 2025:blood.2025029006. https:\/\/doi.org\/10.1182\/blood.2025029006.","DOI":"10.1182\/blood.2025029006"},{"key":"10.1016\/j.tracli.2026.01.009_b0090","first-page":"409","article-title":"Potential use of IgG endopeptidase in the management of platelet refractoriness due to HLA alloimmunization","volume":"57","author":"Burner","year":"2018","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"10.1016\/j.tracli.2026.01.009_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31412","article-title":"Imlifidase utilization in Glanzmann Thrombasthenia with Anti-GPIIb\/IIIa and Anti-HLA alloimmunization and severe platelet refractoriness following hematopoietic stem cell transplant","volume":"72","author":"AlNajjar","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.tracli.2026.01.009_b0100","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/ajt.14733","article-title":"Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients","volume":"18","author":"Lorant","year":"2018","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.tracli.2026.01.009_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2022.951360","article-title":"New approach to desensitization in solid organ transplantation-imlifidase","volume":"1","author":"Durlik","year":"2022","journal-title":"Front Transplant"},{"key":"10.1016\/j.tracli.2026.01.009_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156971","article-title":"FcRn inhibitors in immune thrombocytopenia: a comprehensive review of therapeutic advances and clinical outcomes","volume":"193","author":"Nilforoushzadeh","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.tracli.2026.01.009_b0115","first-page":"200","article-title":"Relative importance of immune and non-immune causes of platelet refractoriness","volume":"66","author":"Doughty","year":"1994","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.01.009_b0120","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/trf.12175","article-title":"Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review","volume":"53","author":"Pavenski","year":"2013","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2026.01.009_b0125","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/trf.16358","article-title":"Platelet transfusion refractoriness and anti-HLA immunization","volume":"61","author":"Blandin","year":"2021","journal-title":"Transfusion (Paris)"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:39Z","timestamp":1777581459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782026000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1246782026000212"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2026.01.009","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practice variability in the evaluation and management of HLA alloimmunization in platelet refractoriness: a multi-institutional survey in the USA","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 francophone de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}